Objective: To compare the effects of different dosages of rhG-CSF on duration of aleucocytosis and white blood cell counts after chemotherapy of patients with hematologic malignancies.
Methods: Ninety patients in our hospital from December 2011 to June 2016 were chosen as study objects, and all of them were divided into 3 groups: group A (rhG-CSF 200 µg/m2), group B(rhG-CSF 300 µg/m2) and group C(rhG-CSF 400 µg/m2); 30 patients from January 2004 to January 2007 were chosen as control(control group). The WBC(min) and its duration, WBC(max) and its timepoint were compared among different groups. The infection rate, incidence of side reactions and total amount of rhG-CSF used in different groups were compared.
Results: In control group, WBC(min) was(1.30±0.11)×109/L, its duration was (3.2±0.7)d, WBC(max) was(5.14±0.41)×109/L, and its time point was (26.1±1.8)d; these in group A were (3.14±0.23)×109/L,(2.7±1.0)d, (10.08±0.69)×109/L and (14.9±1.8)d respectively; these in group B were (3.11±0.32)×109/L, (0.9±0.5)d, (10.17±0.75)×109/L and(10.7±1.5)d respectively; these in group C were (3.15±0.30)×109/L,(0.5±0.3)d, (11.95±0.86)×109/L and (10.6±1.5)d, respectively. Compared with control group, the WBC(min) and WBC(max) were both increased significantly, the duration of WBC(min) was shortened and the timepoint of WBC(max) was moved up(P<0.05). The infection rate of group C (3.33%(1/30)) was significantly lower than that of control group(33.33%(10/30))(P<0.05), total used amount of rhG-CSF and incidence of side reactions were not statistically different among group A,B,C(P>0.05).
Conclusion: Compared with low dosage of rhG-CSF, medium/high dosage of rhG-CSF can help to shorten duration of a leukocytosis after chemotherapy of patients.